|
The said drug is equivalent to reference listed drug, Silenor tablets. Doxepin is used to treat a certain sleep problem (insomnia). It is expected to help stay asleep longer and reduce the number of times a person wakes up during the night. It belongs to a class of drugs known as tricyclic antidepressants.
The drug will be manufactured at the group's formulation manufacturing facility at Moraiya.
Acoording to IQVIA MAT June 2023, Doxepin tablets, had annual sales of $43.4 million in the United States.
The group now has 376 approvals and has so far filed over 444 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The pharma company reported 109.7% surge in net profit to Rs 1,086.9 crore in Q1 FY24 as compared with Rs 518.3 crore posted in Q1 FY23. Revenue from operations jumped 29.6% to Rs 5,139.6 crore during the quarter as compared with Rs 3,964.4 crore recorded in same quarter last year.
The scrip rose 0.02% to currently trade at Rs 644.80 on the BSE.
|